Jeff Wongskhaluang, MD
Ophthalmology · Olathe, KSNPI 1821228677
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (34.2%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Biotissue Holdings Inc. accounts for 84.0% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2023 at $14,285 and has fallen 74.9% since, to $3,585 in 2025. Among ophthalmology clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 149 payments — averaging $281.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$35K
- Glaukos Corporation$3K
- Sight Sciences, Inc.$624
- Alcon$559
- Sun Pharmaceutical Industries Inc.$390
- Maculogix, Inc.$350
- plus $1K from 18 others
What the payments were for
- Consulting fees$14,35034%
- Speaking & faculty fees$6,37615%
- Travel & lodging$13,48032%
- Food & beverage$7,77919%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 56 | $35,272 |
| Glaukos Corporation | 27 | $3,432 |
| Sight Sciences, Inc. | 8 | $624 |
| Alcon | 14 | $559 |
| Sun Pharmaceutical Industries Inc. | 9 | $390 |
| Maculogix, Inc. | 1 | $350 |
| Rxsight Inc | 5 | $345 |
| Ocular Therapeutix, Inc. | 3 | $259 |
| Rayner Intraocular Lenses Limited | 1 | $126 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $125 |
| Dompe US, Inc. | 3 | $69 |
| The Cameron-ehlen Group, Inc. | 3 | $64 |
| AbbVie(2 entities) | 3 | $64 |
| Mallinckrodt Hospital Products Inc. | 2 | $42 |
| Bausch & Lomb Americas Inc. | 2 | $39 |
| Travere Therapeutics, Inc. | 2 | $38 |
| Novartis | 2 | $35 |
| NEW World Medical,inc. | 1 | $29 |
| Harrow Eye, LLC | 1 | $27 |
| Thea Pharma Inc. | 1 | $25 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Tarsus Pharmaceuticals, Inc. | 1 | $23 |
| Kala Pharmaceuticals, Inc. | 1 | $22 |
| Oyster Point Pharma, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$4,243
- NEOX$2,500
- CLARIX$2,500
- AmnioGraft$1,517
- iStent inject Trabecular Micro-Bypass Stent System$763
- OMNI(R) SURGICAL SYSTEM (US)$558
- Ophthalmic Surgical Adjuncts$375
- KXL System$369
- AdaptDx$350
- iStent$334
- iStent inject W$334
- RXSIGHT CONTACT LENS$292
- RXSIGHT INJECTOR CARTRIDGE$292
- RXSIGHT INJECTOR HANDPIECE$292
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$292
- LIGHT ADJUSTABLE LENS (LAL)$292
- iStent Trabecular Micro-Bypass Stent System$263
- DEXTENZA$249
- CEQUA$229
- Clareon$150
How this compares
$41,999 in reported general payments places this provider in the 95th percentile of 135 ophthalmology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 30 | $33,406 |
| Prednisolone Acetate | 560 | $28,138 |
| XiidraLifitegrast | 28 | $25,666 |
| CequaCyclosporine | 28 | $15,470 |
| MoxifloxacinMoxifloxacin Hcl | 609 | $13,487 |
| Ketorolac Tromethamine | 492 | $9,663 |
| Cyclosporine | 13 | $5,566 |
| ValacyclovirValacyclovir Hcl | 44 | $2,415 |
| Latanoprost | 146 | $1,886 |
| Doxycycline Hyclate | 57 | $1,758 |
| Timolol Maleate | 116 | $1,497 |
| Brimonidine Tartrate | 81 | $1,119 |
| ErythromycinErythromycin Base | 107 | $1,099 |
| Acyclovir | 26 | $875 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 53 | $621 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $64 | $33,40630 claims |
| Bausch & Lomb Americas Inc.Xiidra | $39 | $25,66628 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $390 | $15,47028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 135 ophthalmology providers in Kansas.
Other ophthalmology in Olathe
- Brian HeinigerOlathe$4K
- Milton GrinOlathe$3K
- Cooper RodgersOlathe$2K
- Daniel DurrieOverland Park$974K
- John DoaneLeawood$496K
- John HunkelerOverland Park$218K
- Christopher PoleOverland Park$129K
- Blake CooperLenexa$100K
- Miranda BisharaPrairie Village$45K
- Michael EllisLenexa$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.